Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 12:13:960112.
doi: 10.3389/fphar.2022.960112. eCollection 2022.

Advances in the roles and mechanisms of lignans against Alzheimer's disease

Affiliations
Review

Advances in the roles and mechanisms of lignans against Alzheimer's disease

Na Han et al. Front Pharmacol. .

Abstract

Background: Alzheimer's disease (AD) is a serious neurodegenerative disease associated with the memory and cognitive impairment. The occurrence of AD is due to the accumulation of amyloid β-protein (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain tissue as well as the hyperphosphorylation of Tau protein in neurons, doing harm to the human health and even leading people to death. The development of neuroprotective drugs with small side effects and good efficacy is focused by scientists all over the world. Natural drugs extracted from herbs or plants have become the preferred resources for new candidate drugs. Lignans were reported to effectively protect nerve cells and alleviate memory impairment, suggesting that they might be a prosperous class of compounds in treating AD. Objective: To explore the roles and mechanisms of lignans in the treatment of neurological diseases, providing proofs for the development of lignans as novel anti-AD drugs. Methods: Relevant literature was extracted and retrieved from the databases including China National Knowledge Infrastructure (CNKI), Elsevier, Science Direct, PubMed, SpringerLink, and Web of Science, taking lignan, anti-inflammatory, antioxidant, apoptosis, nerve regeneration, nerve protection as keywords. The functions and mechanisms of lignans against AD were summerized. Results: Lignans were found to have the effects of regulating vascular disorders, anti-infection, anti-inflammation, anti-oxidation, anti-apoptosis, antagonizing NMDA receptor, suppressing AChE activity, improving gut microbiota, so as to strengthening nerve protection. Among them, dibenzocyclooctene lignans were most widely reported and might be the most prosperous category in the develpment of anti-AD drugs. Conclusion: Lignans displayed versatile roles and mechanisms in preventing the progression of AD in in vitro and in vivo models, supplying potential candidates for the treatment of nerrodegenerative diseases.

Keywords: Alzheimer’s disease; dibenzocyclooctene lignans; lignans; mechanism; nerve protection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Pathogenesis of AD (The pathogenesis of AD include vascular regulation disorder, infection, diabetes, inflammatory, oxidative stress, the cholinergic hypothesis, glutamic acid pathway and gut microbiology.).
FIGURE 2
FIGURE 2
Structure of compounds 1–31.
FIGURE 3
FIGURE 3
The main mechanisms of dibenzocyclooctene lignans against AD. (Dibenzocyclooctene lignans play a protective role in the nervous system through anti-inflammation, antioxidation and inhibition of neuronal apoptosis. Compounds 113 inhibited the activity of NO, compounds 11 and 13 inhibited the release of downstream inflammatory factors by regulating TLR-4-mediated NF-κB and MAPKs signaling pathways, MyD88/IKK/NF-κB and HSPA12B/PI3K/Akt signaling pathways. In addition, Compounds 10 and 12 up-regulated the expression of SOD and GSH, and inhibited MDA in brain tissue, while compounds 11 and 13 reduced the content of ROS to resist oxidative stress. Compound 13 also inhibited apoptosis by inhibiting JNK-mediated PDH inhibition.).

References

    1. Ali T. B., Schleret T. R., Reilly B. M., Chen W. Y., Abagyan R. (2015). Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the united-states and Canada. PLoS ONE 10 (12), e0144337 10.1371/journal.pone.0144337 - DOI - PMC - PubMed
    1. Andargie M., Vinas M., Rathgeb A., Moller E., Karlovsky P. (2021). Lignans of sesame (sesamum indicum L.): A comprehensive review. Molecules 26 (4), 883. 10.3390/molecules26040883 - DOI - PMC - PubMed
    1. Banks W. A., Owen J. B., Erickson M. A. (2012). Insulin in the brain: There and back again. Pharmacol. Ther. 136 (1), 82–93. 10.1016/j.pharmthera.2012.07.006 - DOI - PMC - PubMed
    1. Behl T., Kaur I., Sehgal A., Singh S., Sharma N., Makeen H. A., et al. (2022). "“Aducanumab” making a comeback in alzheimer’s disease: An old wine in a new bottle." Biomed. Pharmacother. 148: 112746 10.1016/j.biopha.2022.112746 - DOI - PubMed
    1. Bostanciklioglu M. (2019). The role of gut microbiota in pathogenesis of Alzheimer's disease. J. Appl. Microbiol. 127 (4), 954–967. 10.1111/jam.14264 - DOI - PubMed

LinkOut - more resources